For example, febuxostat, a potent non-purine xanthine oxidase inhibitor and generally considered a second-line urate-lowering therapy [1], was included in Class B of the Chinese National Health Insurance Catalog in 2019 [35], which greatly reduced the medication burden of patients with gout. This evidence concerns the gene XDH and gout.